The analysis included a substantial population of 58,452 patients, during which 80 cases of TD were identified and matched with a control group in a 1:10 ratio.

The authors of the study stressed that prescribing high doses of antipsychotics carries a considerable risk of developing TD, particularly in patients receiving over 300 mg per day.

A recent study led by Maki Gouda from Mitsubishi Tanabe Pharma Corporation in Osaka examined the risks associated with high doses of antipsychotic medications in patients aged 15 and older diagnosed with schizophrenia, depression, or bipolar disorder.

Published in the Journal of Clinical Psychopharmacology, the research highlights that antipsychotic doses exceeding 75 mg per day significantly increase the risk of tardive dyskinesia (TD).

The findings revealed a strong correlation between both the last prescription dose and the maximum dose prior to TD diagnosis exceeding 75 mg per day and a heightened risk of developing TD.

Post-hoc analyses further indicated that doses of 300 mg per day or more were linked to even greater risks of TD, with odds ratios of 3.40 and 3.50 compared to those on lower doses.

This study underscores the critical need for healthcare providers to closely monitor patients on antipsychotic medications for potential TD risks.